Oncobiologics, which is developing biosimilars of blockbuster drugs Humira and Avastin, raised $35 million by offering 5.8 million units at $6.
Oncobiologics plans to list on the Nasdaq under the symbol ONS. Jefferies and Barclays acted as lead managers on the deal.